Intended Audience
Registration
Participation in this iQ&A interactive Medical Intelligence Zone for Multiple Sclerosis is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.
Grantor Support
Supported by an independent educational grant from Teva Neuroscience
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School, Office of CME and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Massachusetts Medical School designates this educational activity for a maximum of 3.0 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.
Policy on Faculty & Provider Disclosure
It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.
Program Faculty and Disclosure
Ben W. Thrower, MD
Medical Director
MS Institute at Shepherd Center
Clinical Instructor, Neurology
Emory University
Atlanta, GA
Consultant: Teva Neuroscience
Speaker: Teva Neuroscience
Research support: Acorda
Daniel Pelletier, MD
Professor
Departments of Neurology and Radiology
Andy and Debbie Rachleff Distinguished Professor of Neurology
Director, Advanced Imaging in Multiple Sclerosis (AIMS) Laboratory
University of California San Francisco
San Francisco, California
Nothing to disclose
Patricia Coyle, MD
Acting Chair, Department of Neurology
Professor of Neurology
Department of Neurology
Director, Multiple Sclerosis (MS) Comprehensive Care Center
School of Medicine, Stony Brook, (SUNY)
Stony Brook, New York
Grant/research support: sanofi-aventis and Novartis
Consultant: Bayer, Biogen-Idec, EMD Serono, Pfizer, TEVA Pharmaceuticals, sanofi- aventis, and Novartis
Speaker’s bureau: Bayer, Biogen-Idec, EMD Serono, Pfizer, TEVA Pharmaceuticals
Fred D. Lublin, MD
Saunders Family Professor of Neurology
Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Mount Sinai Medical Center
New York, New York
Research Support: Acorda Therapeutics, Inc.; Biogen Idec; Genentech, Inc.; Novartis Pharmaceuticals Corp; Teva Neuroscience, Inc.; Genzyme; Sanofi- Aventis; NIH; NMSS
Consulting Agreements/Advisory Boards/DSMB: Bayer HealthCare Pharmaceuticals; Biogen Idec; BioMS Medical Corp.; EMD Serono, Inc.; Genentech, Inc.; Novartis; Pfizer; Teva Neuroscience; Genmab; Medicinova; Actelion; Allozyne, Sanofi-Aventis, Acorda, Questcor, Avanir, Roche, Celgene, Abbott
Speakers’ Bureau/Honorarium Agreements: EMD Serono; Pfizer; Teva Neuroscience;
Current Financial Interests/Stock Ownership: Cognition Pharmaceuticals, Inc.
Jerry S. Wolinsky, MD
Bartels Family and Opal C. Rankin Professor of Neurology
Director, Multiple Sclerosis Research Group and
Magnetic Resonance Imaging Analysis Center
The University of Texas Health Science Center at Houston
Houston, Texas
Grant/research support: National Institutes of Health, sanofi-aventis, and Clayton Foundation for Research
Consulting fees: Teva Pharmaceuticals, Teva Neurosciences, Genentech, Inc., sanofi-aventis, Bayer, EMD Serono, Glycominds, Novartis, Antisense Therapeutics, Ltd., UCB, and Novartis
Rohit Bakshi, MD, MPH
Director, Laboratory for Neuroimaging Research
Partners Multiple Sclerosis Center
Associate Professor of Neurology & Radiology
Brigham & Women’s Hospital, Harvard Medical School
Boston, Massachusetts
Grant/Research Support: Teva Neuroscience, Biogen Idec, EMD, Serono
Corey C. Ford, MD, PhD
Professor of Neurology
Director, UNM Multiple Sclerosis Specialty Clinic
Past President, Consortium of Multiple Sclerosis Centers
Albuquerque, New Mexico
Consultant or performed clinical trials: Acorda, Bayer HealthCare, Biogen IDEC, BioMS Technologies, Elan, EMD Serono, Genentech, Genzyme, Novartis, Sanofi-Aventis, and Teva Neuroscience
Aaron E. Miller, MD
Professor of Neurology and Medical Director
The Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Mount Sinai School of Medicine
New York, NY
Consultant: Acorda, Biogen-Idec, Ono, Glaxo SmithKline, sanofi-aventis, Novartis, Teva Neurocience, EMD Serono, Daiichi-Sankyo
Speaker’s Bureau: Acorda, Biogen-Idec, Teva Neurocience, EMD Serono
Research Support: Acorda, Biogen-Idec, Genentech, Genzyme, Teva Neurocience
Douglas R. Jeffery, MD, PhD
Associate Professor of Neurology
Department of Neurology
Director, Multiple Sclerosis Center
Wake Forest University School of Medicine
Winston-Salem, North Carolina
Grant/Research Support: Bayer HealthCare Pharmaceuticals, Biogen Idec Inc., GlaxoSmithKline, and Teva Neuroscience
Advisor/Consultant: Bayer HealthCare Pharmaceuticals, Biogen Idec Inc., EMD Serono, Inc., GlaxoSmithKline, and Teva Neuroscience.
Speakers’ Bureau: Bayer HealthCare Pharmaceuticals, Biogen Idec Inc., GlaxoSmithKline, and Teva Neuroscience
Norman Kachuck, MD
Associate Professor of Neurology
Chief, Neuroimmunology Division,
Department of Neurology
Director, Multiple Sclerosis Comprehensive Care Center and Research Group
Vice-Chair, Health Sciences IRB
University of Southern California Keck School of Medicine
Los Angeles, California
Nothing to disclose
Kenneth P. Johnson, MD
Professor of Neurology
Director, Maryland Center for Multiple Sclerosis
University of Maryland Medical Center
Baltimore, MD
Consultant: Teva Pharmaceuticals
Speaker’s Bureau: Teva Pharmaceuticals
Robert P. Lisak, MD, FAAN, FRCP
Parker Webber Chair in Neurology
Professor and Chair of Neurology
Professor of Immunology and Microbiology
Wayne State University School of Medicine
Neurologist-in-Chief
Detroit Medical Center
Chief of Neurology
Harper University Hospital
Detroit, MI
Consultant: Teva Neuroscience, Questcor
Speaker: TevaNeurocience
Research Support: Teva Neuroscience, Questcor
Program Managers and Web Editor Disclosure Program Manager Gideon Bosker, MD have nothing to disclose.
Program Reviewers Denise Leary and Richard Aghababian, MD have nothing to disclose.
Educational Objectives
Upon completion of this activity, participants will:
Disclaimer
Copyright © 2010 by CMEducation Resources, LLC All rights reserved.
Reproduction, distribution, or translation without express written permission is strictly prohibited.
Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.
Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.
Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, or the program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.
This complimentary CME educational activity is designed for all neurology-focused physicians, nurses, NPs, academicians, pharmacists, researchers, investigators, and program directors managing, referring, and/or consulting on patients with neurological disorders, with a focus on multiple sclerosis. We welcome neurology-focused clinicians with a medical and educational needs in the fields of general neurology, multiple sclerosis, internal medicine, and other providers that are part of the multidisciplinary team caring for patients with these and related conditions.
Registration
Participation in this iQ&A interactive Medical Intelligence Zone for Multiple Sclerosis is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.
Grantor Support
Supported by an independent educational grant from Teva Neuroscience
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School, Office of CME and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Massachusetts Medical School designates this educational activity for a maximum of 3.0 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.
Policy on Faculty & Provider Disclosure
It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.
Program Faculty and Disclosure
Ben W. Thrower, MD
Medical Director
MS Institute at Shepherd Center
Clinical Instructor, Neurology
Emory University
Atlanta, GA
Consultant: Teva Neuroscience
Speaker: Teva Neuroscience
Research support: Acorda
Daniel Pelletier, MD
Professor
Departments of Neurology and Radiology
Andy and Debbie Rachleff Distinguished Professor of Neurology
Director, Advanced Imaging in Multiple Sclerosis (AIMS) Laboratory
University of California San Francisco
San Francisco, California
Nothing to disclose
Patricia Coyle, MD
Acting Chair, Department of Neurology
Professor of Neurology
Department of Neurology
Director, Multiple Sclerosis (MS) Comprehensive Care Center
School of Medicine, Stony Brook, (SUNY)
Stony Brook, New York
Grant/research support: sanofi-aventis and Novartis
Consultant: Bayer, Biogen-Idec, EMD Serono, Pfizer, TEVA Pharmaceuticals, sanofi- aventis, and Novartis
Speaker’s bureau: Bayer, Biogen-Idec, EMD Serono, Pfizer, TEVA Pharmaceuticals
Fred D. Lublin, MD
Saunders Family Professor of Neurology
Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Mount Sinai Medical Center
New York, New York
Research Support: Acorda Therapeutics, Inc.; Biogen Idec; Genentech, Inc.; Novartis Pharmaceuticals Corp; Teva Neuroscience, Inc.; Genzyme; Sanofi- Aventis; NIH; NMSS
Consulting Agreements/Advisory Boards/DSMB: Bayer HealthCare Pharmaceuticals; Biogen Idec; BioMS Medical Corp.; EMD Serono, Inc.; Genentech, Inc.; Novartis; Pfizer; Teva Neuroscience; Genmab; Medicinova; Actelion; Allozyne, Sanofi-Aventis, Acorda, Questcor, Avanir, Roche, Celgene, Abbott
Speakers’ Bureau/Honorarium Agreements: EMD Serono; Pfizer; Teva Neuroscience;
Current Financial Interests/Stock Ownership: Cognition Pharmaceuticals, Inc.
Jerry S. Wolinsky, MD
Bartels Family and Opal C. Rankin Professor of Neurology
Director, Multiple Sclerosis Research Group and
Magnetic Resonance Imaging Analysis Center
The University of Texas Health Science Center at Houston
Houston, Texas
Grant/research support: National Institutes of Health, sanofi-aventis, and Clayton Foundation for Research
Consulting fees: Teva Pharmaceuticals, Teva Neurosciences, Genentech, Inc., sanofi-aventis, Bayer, EMD Serono, Glycominds, Novartis, Antisense Therapeutics, Ltd., UCB, and Novartis
Rohit Bakshi, MD, MPH
Director, Laboratory for Neuroimaging Research
Partners Multiple Sclerosis Center
Associate Professor of Neurology & Radiology
Brigham & Women’s Hospital, Harvard Medical School
Boston, Massachusetts
Grant/Research Support: Teva Neuroscience, Biogen Idec, EMD, Serono
Corey C. Ford, MD, PhD
Professor of Neurology
Director, UNM Multiple Sclerosis Specialty Clinic
Past President, Consortium of Multiple Sclerosis Centers
Albuquerque, New Mexico
Consultant or performed clinical trials: Acorda, Bayer HealthCare, Biogen IDEC, BioMS Technologies, Elan, EMD Serono, Genentech, Genzyme, Novartis, Sanofi-Aventis, and Teva Neuroscience
Aaron E. Miller, MD
Professor of Neurology and Medical Director
The Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Mount Sinai School of Medicine
New York, NY
Consultant: Acorda, Biogen-Idec, Ono, Glaxo SmithKline, sanofi-aventis, Novartis, Teva Neurocience, EMD Serono, Daiichi-Sankyo
Speaker’s Bureau: Acorda, Biogen-Idec, Teva Neurocience, EMD Serono
Research Support: Acorda, Biogen-Idec, Genentech, Genzyme, Teva Neurocience
Douglas R. Jeffery, MD, PhD
Associate Professor of Neurology
Department of Neurology
Director, Multiple Sclerosis Center
Wake Forest University School of Medicine
Winston-Salem, North Carolina
Grant/Research Support: Bayer HealthCare Pharmaceuticals, Biogen Idec Inc., GlaxoSmithKline, and Teva Neuroscience
Advisor/Consultant: Bayer HealthCare Pharmaceuticals, Biogen Idec Inc., EMD Serono, Inc., GlaxoSmithKline, and Teva Neuroscience.
Speakers’ Bureau: Bayer HealthCare Pharmaceuticals, Biogen Idec Inc., GlaxoSmithKline, and Teva Neuroscience
Norman Kachuck, MD
Associate Professor of Neurology
Chief, Neuroimmunology Division,
Department of Neurology
Director, Multiple Sclerosis Comprehensive Care Center and Research Group
Vice-Chair, Health Sciences IRB
University of Southern California Keck School of Medicine
Los Angeles, California
Nothing to disclose
Kenneth P. Johnson, MD
Professor of Neurology
Director, Maryland Center for Multiple Sclerosis
University of Maryland Medical Center
Baltimore, MD
Consultant: Teva Pharmaceuticals
Speaker’s Bureau: Teva Pharmaceuticals
Robert P. Lisak, MD, FAAN, FRCP
Parker Webber Chair in Neurology
Professor and Chair of Neurology
Professor of Immunology and Microbiology
Wayne State University School of Medicine
Neurologist-in-Chief
Detroit Medical Center
Chief of Neurology
Harper University Hospital
Detroit, MI
Consultant: Teva Neuroscience, Questcor
Speaker: TevaNeurocience
Research Support: Teva Neuroscience, Questcor
Program Managers and Web Editor Disclosure Program Manager Gideon Bosker, MD have nothing to disclose.
Program Reviewers Denise Leary and Richard Aghababian, MD have nothing to disclose.
Educational Objectives
Upon completion of this activity, participants will:
- Better understand the date, expert analysis, and evidence supporting the foundation role of immunomodulation therapy (IMT) for long-term efficacy, safety, neuronal preservation, and disability mitigation in MS
- Be better able, in the clinical setting, to balance efficacy benefits against safety risks to achieve long-term efficacy with IMT
- Become more clinically skilled at applying evidence and conclusions from long-term follow-up trials with IMT to the front lines of MS practice
- Be better able to apply first-line therapy with immune-modulating agents (IMTs) to specific patient subgroups with MS
- Be better able to understand the efficacy and safety issues associated with immunosuppressive agents for MS, with a focus on patient selection, monitoring, risks for infection, and mechanisms of action
- Become more clinically proficient, based on clinical trial data, at optimizing long-term functional and financial outcomes in RRMS with immunomodulation therapy
Disclaimer
Copyright © 2010 by CMEducation Resources, LLC All rights reserved.
Reproduction, distribution, or translation without express written permission is strictly prohibited.
Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.
Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.
Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, or the program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.
Copyright © CMEducation Resources, LLC
Click here to indicate that you have read this CME information statement and wish to participate in this CME activity.
